Basic Information for Patients About Buprenorphine


Basic Information About Buprenorphine

Federal Law

For the first time in nearly a century physicians may now treat opiate addiction. On October 17, 2000 Title XXXV of the Children’s Health Act of 2000 was enacted that permits the prescribing of certain medications to treat opiate addiction. Physicians may now prescribe Schedule III, IV, and V medications that are approved by the FDA for either maintenance or detoxification.

Only one medication has been approved – buprenorphrine with expectations of other medications receiving approval.


What is Buprenorphine?

Buprenorphine is an agonist/antagonist narcotic medication with partial agonist properties. Buprenorphine was initially developed to treat pain however it has been discovered that it is also a good medication to treat opiate addiction.

As an agonist buprenorphine has a partial opiate agonist properties. The easiest way to understand this is means that it only produces minimal opiate effects. Yes it will produce euphoria and can also produce respiratory depression but this is rare in comparison to opiates such as morphine.

When buprenorphine is prescribed in low doses it is sufficient for opioid-dependent individuals to stop their use of opiates and without experiencing any withdrawal symptoms. These effects are dose dependent and then reach a plateau where no effects are produced. This is referred to as the ceiling effect. For this reason buprenorphine is considered to have a reduced addiction liability. Their are also fewer side effects because of this property.

At high doses buprenorphine can block opioid agonists and can precipitate withdrawal symptoms in an acutely opioid-intoxicated individual. These are antagonist properties and for this reason it is sometimes referred to as an agonist/antagonist.

Subutex and Suboxone?

Subutex and Suboxone are the only substances that have received FDA approval to treat opioid addiction. Subutex and Suboxone are tradenames.

  • Suboxone contains two medications buprenorphine and which is a pain medication and naloxone which blocks the effects of opiate drugs and is used to treat overdose.
  • Why is naloxone added? It was added to keep patients from “shooting up” or injecting buprenorphine. If you inject Suboxone you will get withdrawal symptoms.
  • Subutex contains only buprenorphine. It is used at the beginning of treatment because the naloxone in Suboxone can cause withdrawal symptoms and for other special circumstances. So patients can be started on Subutex and then switched to Suboxone.

Can Buprenex be Prescribed?

No, Buprenex is not approved for treatment of opioid addiction. And the status of methadone and LAAM are also unchanged. They still can be only dispensed, not prescribed, for opioid addiction, and only at Federally regulated OTPs.

How is Suboxone Prescribed?

You doctor will tell you how to take it. It is dissolved under the tongue and you need to let it completely disolve because that way the naloxone is inactivated.

Suboxone comes in two dosage forms: 2 mg buprenorphine/0.5 mg naloxone and 8 mg buprenorphine/2 mg naloxone. Subutex comes in 2 mg and 8 mg strengths.

What is the Difference Between Suboxone and Methadone?

During the past year many articles appearing the media have given the impression that Suboxone is equal or even more effective than methadone. It is not! Although it is new the patients that seem to benefit the most from Suboxone have shorter histories of opiate addiction. Most methadone patients that have attempted to switch to Suboxone from methadone because they want to leave the clinic system find that it does not work for them. For this reason it is recommended that patients starting Suboxone and new in treatment keep an open mind because if they continue to experience drug craving then they probably need methadone treatment.

How Do I Find a Doctor?

SAMHSA has set up the Buprenorphrine Physician Locator that allows you to search for a physician by state. Presently about 1200 doctors have applied to prescribe Suboxone.


Buprenorphrine Physician Locator


SAMHSA Links


About Buprenorphrine


FAQs



Food and Drug Administration Links


FDA Subutex and Suboxone tablets


FDA Talk Paper


Drug Label (PDF Format)
 


Patient Leaflet (PDF Format)
 


FDA Questions and Answers


Other Resources


Buprenorpine An Alternative Treatment for Opioid Dependence
. Blaine, J. (editor). NIDA Research Monograph 121. Rockville: DHHS, 1992.


Buprenorphine Approval Expands Options for Addiction Treatment
. NIDA Notes November 2002, Vol. 17, No. 4

Similar Posts

  • Carmen Beatrice Pearman Arlt, LMSW, CAC, CMA 1955 – 2019

    Admin 03/01/2023

    Carmen Beatrice Pearman Arlt, LMSW, CAC, CMA 1955 – 2019 NAMA Recovery    Press Release    May 6, 2019  |  0 National Alliance for Medication Assisted RecoveryPress ReleaseContacts Persons: Joycelyn Woods, Executive Director, [email protected]Carmen Pearman-Arlt, President, [email protected]♰Phone/Fax: 1.212.595.NAMA  (1-212-595-62620For ReleaseMay 6, 2019 64, passed away December 9, 2018 after a long illness.In the early 1990s NAMA Recovery was…

  • News

    Admin 08/25/2022

    Congratulations to Sara Gefvert, the 2022 Lane/Holden Award Winner! November 2, 2022 The 2022 Richard Lane/Robert Holden Patient Advocacy Award was presented at an Awards Reception held in conjunction with the 2022 Conference of the American Association for the Treatment of Opioid Dependence (AATOD) in Baltimore, Maryland on November 2, 2022. Richard Lane/Robert Holden Patient…

  • The National Methadone Conference

    Admin 03/14/2023

    Sponsored by American Association for the Treatment of Opioid Dependence Washington, D.C. ~ April 13-16, 2003 Saturday, April 12, 2003 Pre-Conference Session  NAMA offers special thanks to Mallinckrodt. We also wish to thank Haworth Press, Vista Pharmaceuticals, Bendiner Labs, NIDA, and CSAT without whose support the first Certified Methadone Advocate (CMA) Training Course would not…

  • Hepatitis C Committee

    Admin 10/16/2021

    Chair: Dr. P. Kishore, MD, MPH, CMA (Boston NAMA) Committee Members Paul Bowman, CMA  Cheri Jarvis, CMA  The HCV Committee was created to empower methadone patients through education and advocacy and to provide support for those that do test positive for Hepatitis C. What Is Hepatitis C? Hepatitis is an inflammation of the liver. Although…

  • Publication Index-1

    Admin 09/22/2021

    Changes in Methadone Treatment Practices: Results From a National Panel Study, 1988-2000 by Thomas D’Aunno, PhD; Harold A. Pollack, PhD Journal of the American Medical Association Vol. 288, No. 7 August 21, 2002 Context Results from several studies conducted in the early 1990s showed that the majority of US methadone maintenance programs did not use…

  • Figure 3 The Methadone Molecule

    Admin 05/15/2023

       Contents          The Pharmacology of Opioids  Cont.      Back    Education Series Number 5.1  February 2001 (Revised)  Part 2 continued     Figure 3 The Methadone Molecule.  The two dimensional representation of the methadone molecule is very different from that of morphine. However, molecules are three dimensional and the methadone molecule bends into a structure that is very…